Weekender 8/28/15

To Our New Jersey Life Sciences Community: Welcome to another edition of the Weekender. New Jersey’s life sciences footprint continues to expand with a number of great stories in the news this week…   The U.S. Food and Drug Administration (FDA) has approved Synjardy® (empagliflozin and metformin hydrochloride) tablets, from BioNJ Member Eli Lilly and Company and Boehringer… Read the full article


Weekender 8/21/15

To Our New Jersey Life Sciences Community: Welcome to another edition of the Weekender. We start this week’s Weekender off with a special call out to precious 6-year old Patient Advocate Max Schill, who was diagnosed at the age of one and a half with Rasopathy, called Noonan Syndrome. We are so proud of our Magic Max who hails from… Read the full article


Weekender 8/14/15

To Our New Jersey Life Sciences Community: Welcome to another edition of the Weekender. Exciting news this week for the State of New Jersey. The Board of the New Jersey Economic Development Authority approved Grow New Jersey (Grow NJ) tax credits for Macrocure, Inc., which is developing a platform to address chronic and hard-to-heal wounds, and Polaris Solutions,… Read the full article


Weekender 8/7/15

To Our New Jersey Life Sciences Community: Welcome to another edition of the Weekender. New Jersey’s dynamic life sciences ecosystem continues to be a leader with amazing stories and accomplishments making the news this week. Rutgers Biomedical and Health Sciences Progress Report highlighted a long list of impressive activities, including innovative research studies underway and… Read the full article


Weekender 7/31/15

To Our New Jersey Life Sciences Community: Welcome to another edition of the Weekender.   It has been another exciting week for New Jersey’s robust life sciences ecosystem… Just today, the 2015 Business Facilities Rankings were released with New Jersey ranked #1 in Biotechnology Growth Potential. This comes on the heels of yesterday’s BioSpace story which… Read the full article


Weekender 7/24/15

To Our New Jersey Life Sciences Community: Welcome to another edition of the Weekender. It’s been an important week at BioNJ…one of those where we just cannot contain our excitement! (Actually to be honest, they are all pretty much like that!!!) What has us particularly excited about this week though, is that FDA Commissioner Dr. Stephen Ostroff… Read the full article


Weekender 7/17/15

To Our New Jersey Life Sciences Community: Welcome to another edition of the Weekender. Another Great Week for New Jersey Approvals Basking Ridge-based BioNJ Member Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen, announced that the FDA has approved its supplemental Biologics License Application (sBLA) for Dysport® (abobotulinumtoxinA) for the treatment of upper limb spasticity (ULS) in adult… Read the full article


Weekender 7/10/15

To Our New Jersey Life Sciences Community: Welcome to another edition of the Weekender. LOTS OF GREAT NEWS THIS WEEK:  21st Century Cures Passes House by Wide Margin; Newx2 BioCruise Breaks Record Registration; Novartis Wins FDA Nod; Sanofi/Regeneron Drug Passes Hurdle; Celgene Announces Purchase of Merck Summit Campus; NJ Women Lead Scoring at World Cup An… Read the full article


Weekender 7/2/15

To Our New Jersey Life Sciences Community: Welcome to another edition of the Weekender. Celgene Expansion: Exciting News for the State of New Jersey  and Our Robust Ecosystem! BioNJ Member Celgene Corporation, an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases,… Read the full article


Weekender 6/26/15

To Our New Jersey Life Sciences Community: Welcome to another edition of the Weekender. BIG News for New Jersey Drug Approvals This Week BioNJ Member The Medicines Company announced the approval of KENGREAL™ (cangrelor) by the FDA as an adjunctive therapy to percutaneous coronary intervention (PCI) for reducing periprocedural thrombotic events in patients who have not been… Read the full article